Raiffeisen Bank International AG Buys Shares of 20,000 CRISPR Therapeutics AG $CRSP

Key Points

• Raiffeisen Bank International acquired 20,000 shares of CRISPR Therapeutics in the second quarter, valued at approximately $1.13 million. Institutional investors collectively own 69.2% of the company.
• CRISPR Therapeutics shares opened at $55.79 and were down 1.2%, with the stock trading between a one-year low of $44.12 and high of $78.48. The company reported a quarterly loss of $0.94 per share on $10.18 million in revenue.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $68.06, although ratings range from “Strong Buy” to “Sell.”

Raiffeisen Bank International AG acquired a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 20,000 shares of the company's stock, valued at approximately $1,127,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cerity Partners LLC lifted its holdings in CRISPR Therapeutics by 3.0% in the 2nd quarter. Cerity Partners LLC now owns 6,541 shares of the company's stock worth $318,000 after purchasing an additional 190 shares during the last quarter. Peapack Gladstone Financial Corp increased its stake in CRISPR Therapeutics by 3.0% during the second quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company's stock valued at $339,000 after acquiring an additional 200 shares during the period. Allworth Financial LP raised its stake in shares of CRISPR Therapeutics by 2.7% in the fourth quarter. Allworth Financial LP now owns 9,550 shares of the company's stock valued at $501,000 after purchasing an additional 249 shares in the last quarter. Meeder Advisory Services Inc. raised its stake in shares of CRISPR Therapeutics by 6.6% in the 4th quarter. Meeder Advisory Services Inc. now owns 4,392 shares of the company's stock valued at $230,000 after buying an additional 270 shares in the last quarter. Finally, IFP Advisors Inc lifted its holdings in shares of CRISPR Therapeutics by 29.9% during the 4th quarter. IFP Advisors Inc now owns 1,250 shares of the company's stock worth $66,000 after acquiring an additional 288 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Trading Down 1.2%

CRISPR Therapeutics stock opened at $55.79 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 17.85 and a quick ratio of 17.85. The firm has a 50-day moving average of $53.86 and a 200-day moving average of $52.95. The company has a market cap of $5.39 billion, a price-to-earnings ratio of -11.72 and a beta of 1.76. CRISPR Therapeutics AG has a one year low of $44.12 and a one year high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%.The company had revenue of $10.18 million for the quarter. On average, equities analysts expect that CRISPR Therapeutics AG will post -4.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CRSP. Morgan Stanley set a $60.00 target price on shares of CRISPR Therapeutics and gave the company an "equal weight" rating in a research note on Thursday, June 11th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of CRISPR Therapeutics in a research note on Friday, July 17th. Needham & Company LLC reiterated a "buy" rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a report on Monday, August 31st. Citizens Jmp reiterated a "market outperform" rating and set a $80.00 target price on shares of CRISPR Therapeutics in a research report on Monday, August 31st. Finally, HC Wainwright restated a "buy" rating on shares of CRISPR Therapeutics in a report on Monday, August 31st. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $68.06.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source